These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30670439)

  • 1. Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole.
    Watson JA; Strub-Wourgraft N; Tarral A; Ribeiro I; Tarning J; White NJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.
    Tarral A; Blesson S; Mordt OV; Torreele E; Sassella D; Bray MA; Hovsepian L; Evène E; Gualano V; Felices M; Strub-Wourgaft N
    Clin Pharmacokinet; 2014 Jun; 53(6):565-80. PubMed ID: 24535888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness.
    Kaiser M; Bray MA; Cal M; Bourdin Trunz B; Torreele E; Brun R
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5602-8. PubMed ID: 21911566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.
    Mesu VKBK; Kalonji WM; Bardonneau C; Mordt OV; Blesson S; Simon F; Delhomme S; Bernhard S; Kuziena W; Lubaki JF; Vuvu SL; Ngima PN; Mbembo HM; Ilunga M; Bonama AK; Heradi JA; Solomo JLL; Mandula G; Badibabi LK; Dama FR; Lukula PK; Tete DN; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
    Lancet; 2018 Jan; 391(10116):144-154. PubMed ID: 29113731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fexinidazole: First Global Approval.
    Deeks ED
    Drugs; 2019 Feb; 79(2):215-220. PubMed ID: 30635838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness.
    Torreele E; Bourdin Trunz B; Tweats D; Kaiser M; Brun R; Mazué G; Bray MA; Pécoul B
    PLoS Negl Trop Dis; 2010 Dec; 4(12):e923. PubMed ID: 21200426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease.
    Bahia MT; Nascimento AF; Mazzeti AL; Marques LF; Gonçalves KR; Mota LW; Diniz Lde F; Caldas IS; Talvani A; Shackleford DM; Koltun M; Saunders J; White KL; Scandale I; Charman SA; Chatelain E
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4362-70. PubMed ID: 24841257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study.
    Kande Betu Ku Mesu V; Mutombo Kalonji W; Bardonneau C; Valverde Mordt O; Ngolo Tete D; Blesson S; Simon F; Delhomme S; Bernhard S; Mahenzi Mbembo H; Mpia Moke C; Lumeya Vuvu S; Mudji E'kitiak J; Akwaso Masa F; Mukendi Ilunga M; Mpoyi Muamba Nzambi D; Mayala Malu T; Kapongo Tshilumbwa S; Botalema Bolengi F; Nkieri Matsho M; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
    Lancet Glob Health; 2021 Jul; 9(7):e999-e1008. PubMed ID: 34143998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2-3 trial.
    Kande Betu Kumesu V; Mutombo Kalonji W; Bardonneau C; Valverde Mordt O; Ngolo Tete D; Blesson S; Simon F; Delhomme S; Bernhard S; Nganzobo Ngima P; Mahenzi Mbembo H; Fina Lubaki JP; Lumeya Vuvu S; Kuziena Mindele W; Ilunga Wa Kyhi M; Mandula Mokenge G; Kaninda Badibabi L; Kasongo Bonama A; Kavunga Lukula P; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
    Lancet Glob Health; 2022 Nov; 10(11):e1665-e1674. PubMed ID: 36179736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fexinidazole: A New Drug for African Sleeping Sickness on the Horizon.
    Pollastri MP
    Trends Parasitol; 2018 Mar; 34(3):178-179. PubMed ID: 29275007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 2, Randomized, Multicenter, Placebo-Controlled, Proof-of-Concept Trial of Oral Fexinidazole in Adults With Chronic Indeterminate Chagas Disease.
    Torrico F; Gascón J; Ortiz L; Pinto J; Rojas G; Palacios A; Barreira F; Blum B; Schijman AG; Vaillant M; Strub-Wourgaft N; Pinazo MJ; Bilbe G; Ribeiro I
    Clin Infect Dis; 2023 Feb; 76(3):e1186-e1194. PubMed ID: 35925555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.
    Wyllie S; Patterson S; Stojanovski L; Simeons FR; Norval S; Kime R; Read KD; Fairlamb AH
    Sci Transl Med; 2012 Feb; 4(119):119re1. PubMed ID: 22301556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis.
    Burrell-Saward H; Harris AJ; de LaFlor R; Sallam H; Alavijeh MS; Ward TH; Croft SL
    Int J Antimicrob Agents; 2017 Aug; 50(2):203-209. PubMed ID: 28552771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fexinidazole: a potential new drug candidate for Chagas disease.
    Bahia MT; de Andrade IM; Martins TA; do Nascimento ÁF; Diniz Lde F; Caldas IS; Talvani A; Trunz BB; Torreele E; Ribeiro I
    PLoS Negl Trop Dis; 2012; 6(11):e1870. PubMed ID: 23133682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotoxicity profile of fexinidazole--a drug candidate in clinical development for human African trypanomiasis (sleeping sickness).
    Tweats D; Bourdin Trunz B; Torreele E
    Mutagenesis; 2012 Sep; 27(5):523-32. PubMed ID: 22539226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.
    Khare S; Liu X; Stinson M; Rivera I; Groessl T; Tuntland T; Yeh V; Wen B; Molteni V; Glynne R; Supek F
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6385-94. PubMed ID: 26239982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.
    Jansson-Löfmark R; Na-Bangchang K; Björkman S; Doua F; Ashton M
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1299-307. PubMed ID: 25512417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-(Nitroaryl)-5-Substituted-1,3,4-Thiadiazole Derivatives with Antiprotozoal Activities: In Vitro and In Vivo Study.
    Mousavi A; Foroumadi P; Emamgholipour Z; Mäser P; Kaiser M; Foroumadi A
    Molecules; 2022 Aug; 27(17):. PubMed ID: 36080325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage.
    Francisco AF; Jayawardhana S; Lewis MD; White KL; Shackleford DM; Chen G; Saunders J; Osuna-Cabello M; Read KD; Charman SA; Chatelain E; Kelly JM
    Sci Rep; 2016 Oct; 6():35351. PubMed ID: 27748443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of novel drugs for human African trypanosomiasis.
    Brun R; Don R; Jacobs RT; Wang MZ; Barrett MP
    Future Microbiol; 2011 Jun; 6(6):677-91. PubMed ID: 21707314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.